retatrutide approval status 2025 HAS NOT BEEN APPROVED YET & CURRENTLY IN PHASE III CLINICAL TRIALS⛔️ Retatrutide is not currently FDA-approved, as it is in Phase III clinical trials with anticipated completion in 2025–2026 and Can You Access Retatrutide Before

Medicare Part D coverage expansion: The proposed CMS rule allowing Medicare Part D plans to cover anti-obesity medications would make 31 million Medicare beneficiaries with obesity eligible for semaglutide and tirzepatide, representing a USD 55.8 billion annual drug spend potential at 15% initial penetration

Unexpected complications such as gallbladder inflammation or pancreatitis emerging with long-term use

GLP-1 Medical Weight Loss Recent Articles FREQUENTLY ASKED QUESTIONS Let us ease your weight loss transition by answering the commonly asked questions about our Louisiana Telemed Weight Loss Program

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy

While further research is needed to define the efficacy and safety of GLP-1RAs specifically in IBD, these agents are already widely prescribed for comorbid obesity and T2DM

Health Canada also warned about these risks, as well as the potential for mood swings, blood sugar imbalances, liver or kidney damage, and blood clots